Dr. Ashraf Ibrahim Selected for 2024 Billy H. Cooper Award by the Medical Mycology Society of the Americas (MMSA)

TLI Investigator Ashraf Ibrahim, PhD, has been selected by the Medical Mycology Society of the Americas (MMSA) to receive the 2024 Billy H. Cooper Award for his continuous outstanding achievement in clinical mycology, which is the diagnosis, prevention, and treatment of patients with fungal infections. TLI celebrates and congratulates Dr Ibrahim for receiving this high honor.

Also, the recent award from Scynexis. The below is from TLI Instagram account.

@thelundquistinstitute investigator Dr. Ashraf Ibrahim (X: @Ibrahimlab3) from the Infection and Immunity Institute within an Institute has received a $111,364 contract from SCYNEXIS, Inc. to evaluate their new investigational antifungal drug SCY-247 — a second-generation triterpenoid antifungal agent designed to tackle multi-drug resistant fungal infections.

SCY-247 is advancing through nonclinical development and aims to address critical needs in treating challenging infections like mucormycosis and C. auris. Building on the success of its predecessor, ibrexafungerp (SCY-078), which has already shown promising results and received FDA approval for vulvovaginal candidiasis, SCY-247 could potentially offer both oral and parenteral treatment options.

Dr. Ibrahim’s study is designed to investigate if SCY-247 can potentiate the activity of lower doses and less toxic concentrations of LAMB using the neutropenic mouse model of IPM. This research could be a game-changer in the fight against life-threatening fungal infections with limited treatment options.

To learn more about the groundbreaking work of Dr. Ibrahim, and our Infection and Immunity Institute within an Institute, visit us at https://lundquist.org.